Laxai Life Sciences
India 351 employees Updated 9 July 2026
Laxai Life Sciences is an API manufacturer based in India. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as NAI. Customs aggregates show $1.2M of exports covering 20 molecules to 4 destinations in 2025.
2
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 14 March 2025 NAI US FDA
- 3 August 2019 VAI US FDA
- 24 April 2015 NAI US FDA
- 16 April 2012 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Hyderabad, India | Not on file |
| Medchal-Malkajgiri District, India | 3002806664 |
What they file, and where
| Molecule | Regulators | Docs |
| Raloxifene | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
| EMA | None | 1 |
Scale
| Year | Revenue | Exports | Destinations |
| 2026 YTD | Not reported | $361K | 2 |
| 2025 | Not reported | $1.2M | 4 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Comparing suppliers?
Choose your molecules and target markets. Laxai Life Sciences comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 14 March 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates
- Customs aggregates
- Export values, molecule and destination counts